Molecure 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Marcin Szumowski

최고 경영자

zł473.2k

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	0.7%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

CEO

Marcin Szumowski

no data

테뉴어

zł473,205

보상

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...

리더십 팀

이름	위치	테뉴어	보상	소유권
Marcin Szumowski	Co-Founder	no data	zł473.21k	0.70% PLN 1.2m
Slawomir Broniarek	CFO & Member of the Management Board	no data	zł421.09k	0.20% PLN 355.4k
Zbigniew Zaslona	Chief Scientific Officer & Member of Management Board	2.8yrs	zł473.21k	0.11% PLN 194.6k
Agnieszka Rajczuk-Szczepanska	Member of Management Board & HR Director	4.8yrs	zł348.41k	0.034% PLN 59.7k
Adam Golebiowski	Co-Founder & VP of Research Chemistry	12.8yrs	zł500.00k	3.01% PLN 5.2m
Jacek Olczak	Co-Founder & Head of Medicinal Chemistry	no data	데이터 없음	데이터 없음
Piotr Iwanowski	Chief Medical Officer & Member of Management Board	less than a year	데이터 없음	데이터 없음
Magdalena Tyszkiewicz	Head of CMC	4.8yrs	데이터 없음	데이터 없음
Marta Borkowska	Director of the Management Board Office	2.8yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

경험이 풍부한 관리: MOC 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Luke O'Neill	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bart Lambrecht	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Tomasz Piec	Vice Chairman of the Supervisory Board	4.8yrs	zł133.62k	데이터 없음
Douglas Hay	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Paul Van Der Horst	Independent Chairman of the Supervisory Board	2.8yrs	zł132.99k	0.059% PLN 103.0k
Nancy Van Osselaer	Independent Member of the Supervisory Board	2.8yrs	zł124.22k	데이터 없음
Agnieszka Motyl	Member of the Supervisory Board	1.3yrs	zł44.45k	데이터 없음
Pawel Trawkowski	Independent Member of the Supervisory Board	2.4yrs	zł124.22k	데이터 없음

2.8yrs

평균 재임 기간

경험이 풍부한 이사회: MOC 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Molecure 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Molecure S.A., Annual General Meeting, Jun 13, 2024

Molecure S.A., Annual General Meeting, May 31, 2023

Molecure S.A. Announces Management Changes

Molecure S.A., Annual General Meeting, Jun 30, 2022

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간